As demand for weight-loss drugs rises, states grapple with Medicaid coverage In January, the National Association of Medicaid Directors told the federal Centers for Medicare & Medicaid Services that state Medicaid departments had significant concerns over the fiscal impacts of the Biden proposal to require coverage of GLP-1s, and strongly recommend that CMS maintain the current state option to cover or not cover anti-obesity medications. But others say covering the drugs will yield long-term savings
These over-the-counter products often market themselves as natural alternatives, but they lack clinical backing
At Alternate Health Club , we believe women shouldnt have to choose between results and real life
A clear research agenda prioritizing graft survival, cardiovascular and kidney outcomes, quality of life, cost-effectiveness, and patient-reported outcomesideally via randomized, multicenter or registry-based pragmatic designswill be critical
What You Can Do : Review your denial letter for specific reasons